What is the equity of Orgenesis this year?
Orgenesis has equity of -20.98 M USD this year.
Orgenesis Equity 2024
Orgenesis Equity
-20.98 M USD
Ticker
ORGS
ISIN
US68619K2042
WKN
A2H7XQ
In 2024, Orgenesis's equity was -20.98 M USD, a -176.14% increase from the 27.56 M USD equity in the previous year.
Orgenesis Aktienanalyse
What does Orgenesis do?
Orgenesis Inc is a company specializing in the development of therapies for the treatment of diabetes and other diseases. The company was founded in 2008 to advance research on new therapy approaches for diabetes treatment. Its business model is based on the development of cell therapy technologies to treat patients with diabetes. The company focuses on developing therapies that use human cells to regulate the body's immune system and improve insulin production. Orgenesis Inc also offers consulting services to help other companies develop similar technologies. The company's goal is to provide technology and know-how to drive industrial progress and help people worldwide. Orgenesis Inc is divided into several areas, including biotherapeutics, where it researches and develops therapeutic cell therapies for diabetes and other chronic diseases. It also operates in the engineering services sector, assisting with the design, construction, and development of other therapies and medical devices. The company also distributes products for monitoring diabetes in patients, such as innovative devices that monitor blood glucose and other important parameters, triggering alarms when certain thresholds are exceeded. In summary, Orgenesis Inc is a leading company in the research and development of cell therapy technologies in the field of diabetes and autoimmune therapy. It engages in a wide range of activities, from consulting services to engineering tasks and marketing its own products. This "closed loop" approach of research, development, and marketing has made Orgenesis Inc an innovative company that plays a significant role in the global healthcare industry. Orgenesis ist eines der beliebtesten Unternehmen auf Eulerpool.com.Equity Details
Analyzing Orgenesis's Equity
Orgenesis's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Orgenesis's equity is essential for assessing its financial health, stability, and value to shareholders.
Year-to-Year Comparison
Evaluating Orgenesis's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Impact on Investments
Orgenesis's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Interpreting Equity Fluctuations
Fluctuations in Orgenesis’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Frequently Asked Questions about Orgenesis stock
What was the equity of Orgenesis compared to the previous year?
The equity of Orgenesis has increased/decreased by -176.14% decreased compared to the previous year.
What impact does a high equity have on investors of Orgenesis?
A high equity is advantageous for investors of Orgenesis as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
What impact does low equity have on investors of Orgenesis?
A low equity can be a risk for investors of Orgenesis, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
How does an increase in equity of Orgenesis affect the company?
An increase in equity of Orgenesis can strengthen the company's financial position and improve its ability to make investments in the future.
How does a reduction in the equity of Orgenesis affect the company?
A reduction in equity of Orgenesis can affect the financial situation of the company and lead to a higher dependence on debt capital.
What are some factors that influence the equity of Orgenesis?
Some factors that can affect the equity of Orgenesis include profits, dividend payments, capital increases, and acquisitions.
Why is the equity of Orgenesis so important for investors?
The equity of Orgenesis is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
What strategic measures can Orgenesis take to change the equity?
To change equity, Orgenesis can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
How much dividend does Orgenesis pay?
Over the past 12 months, Orgenesis paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Orgenesis is expected to pay a dividend of 0 USD.
What is the dividend yield of Orgenesis?
The current dividend yield of Orgenesis is .
When does Orgenesis pay dividends?
Orgenesis pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Orgenesis?
Orgenesis paid dividends every year for the past 0 years.
What is the dividend of Orgenesis?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Orgenesis located?
Orgenesis is assigned to the 'Health' sector.
Wann musste ich die Aktien von Orgenesis kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Orgenesis from 9/7/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/7/2024.
When did Orgenesis pay the last dividend?
The last dividend was paid out on 9/7/2024.
What was the dividend of Orgenesis in the year 2023?
In the year 2023, Orgenesis distributed 0 USD as dividends.
In which currency does Orgenesis pay out the dividend?
The dividends of Orgenesis are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Orgenesis
Our stock analysis for Orgenesis Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Orgenesis Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
